2 terminated, 2 withdrawn, 1 active not recruiting, 1 not yet recruiting. 4 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Withdrawn 2, Active not recruiting 1 |
Follow MAA868: new trials by email Literature Review of MAA868 trials Research Report on MAA868
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation Abelacimab - Atrial Fibrillation (AF) | Phase 3 | Not yet recruiting | Novartis Pharmaceuticals | 2500 | 2027-12-30 | 2026-07-31 |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) Abelacimab, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Anthos Therapeutics, Inc. | 2500 | 2022-12-27 | 2026-07-13 |
| A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Abelacimab, Dalteparin - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 417 | 2022-09-27 | 2026-04-17 |
| A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE Abelacimab, Apixaban - Venous Thromboembolism, Deep Venous Thrombosis | Phase 3 | Terminated | Anthos Therapeutics, Inc. | 1150 | 2022-05-05 | 2026-02-23 |
| Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation Abelacimab, Rivaroxaban - Atrial Fibrillation (AF), Stroke | Phase 2 | Active not recruiting | Anthos Therapeutics, Inc. | 1287 | 2021-02-02 | 2025-11-06 |
| Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation MAA868, Apixaban - Atrial Fibrillation | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-10-16 | 2020-10-08 | |
| Prevention of Thromboembolic Events in Total Knee Replacement Patients MAA868, Enoxaparin - Thrombotic Disorders | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2018-10-03 | 2020-10-08 |
Atrial Fibrillation (4) · Venous Thromboembolism (3) · Pulmonary Embolism (2) · Venous Thrombosis (2) · Gastrointestinal Neoplasms (1) · Stroke (1)
Anthos Therapeutics, Inc. (4) · Novartis Pharmaceuticals (3)
Canada (4) · Czechia (4) · Hungary (4) · South Korea (4) · United States (4) · China (3) · Germany (3) · Italy (3) · Latvia (3) · Spain (3) · Sweden (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Austria (2)
PMID 39094433, PMID 39842011, PMID 40546068, PMID 41637102, PMID 42213637
2023 (3), 2017 (2)